Business Segments · Subtotal
North American Pharmaceutical — Subtotal
McKesson North American Pharmaceutical — Subtotal increased by 23.8% to $1.06B in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ3 2024
Last reportedQ4 2025
How to read this metric
Changes in this subtotal reflect shifts in the underlying profitability drivers before final corporate allocations or tax considerations.
Detailed definition
This metric represents an intermediate financial subtotal for the North American Pharmaceutical segment, typically used...
Peer comparison
Commonly used in segment reporting to provide transparency into the build-up of operating profit, consistent with GAAP segment disclosure requirements.
Metric ID:
mck_segment_north_american_pharmaceutical_subtotalHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $347.00M | $744.00M | $852.00M | $1.06B |
| QoQ Change | — | +114.4% | +14.5% | +23.8% |
| YoY Change | — | — | +145.5% | +41.8% |
Range$347.00M – $1.06B
Avg YoY Growth+93.7%
Median YoY Growth+93.7%
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — subtotal?
- McKesson (MCK) reported north american pharmaceutical — subtotal of $1.06B in Q4 2025.
- What does north american pharmaceutical — subtotal mean?
- An intermediate financial subtotal used to reconcile the North American Pharmaceutical segment's performance.